Judit González-Gallego

Judit González-Gallego

Auto-generated profile, based on publicly available information

Judit González-Gallego

Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2025 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
JGJudit González-Gallego
Judit González-Gallego
KTKatalin Todorov-Völgyi
Katalin Todorov-Völgyi
SMStephan Alexander Mueller
Stephan Alexander Mueller
SASophie Antesberger
Sophie Antesberger
MTMihail Ivilinov Todorov
Mihail Ivilinov Todorov
DPDominik Paquet
Dominik Paquet
Blood–brain barrier (BBB) integrity is critical for brain homeostasis, with malfunctions contributing to neurovascular and neurodegenerative disorders. Mechanistic studies on BBB function have been mostly conducted in rodent and in vitro models, which recapitulate some disease features, but have limited translatability to humans and pose challenges for drug discovery. Here we report on a fully human induced pluripotent stem (iPS)-cell-derived, microfluidic three-dimensional (3D) BBB model consisting of endothelial cells (ECs), mural cells and astrocytes. Our model expresses typical fate markers, forms a barrier in vessel-like tubes and enables perfusion, including with human blood. Deletion of FOXF2 in ECs, a major risk gene for cerebral small vessel disease, induced key features of BBB dysfunction, including compromised cell junction integrity and enhanced caveolae formation. Proteomic analysis revealed dysregulated endocytosis and cell junction pathways. Disease features phenocopied those seen in mice with EC-specific Foxf2 deficiency. Moreover, lipid-nanoparticle-based treatment with Foxf2 mRNA rescued BBB deficits, demonstrating the potential for drug development.